Rebamipide is a modern gastrocytoprotector under erosive and ulcerative injuries of upper gastrointestinal tract: results of the research


DOI: https://dx.doi.org/10.18565/therapy.2019.8.173-183

Sagynbaeva V.E., Lazebnik L.B.

1) City clinical hospital No 1 named after N.I. Pirogov of the Department of Healthcare of Moscow; 2) The Department of outpatient therapy of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia
In the article the results of clinical research of Rebagit under erosive and ulcerative injuries of upper gastrointestinal tract with various etiology are shown. After the analysis of the results we concluded that the efficiency of Rebagit treatment was 98,2%, clinically 99% of the patients had no gastrointestinal tract complaints. In case of big and deep ulcers and in case or ulcers found in the patients with cardiovascular or rheumatoid diseases treated with low-dose aspirin (LDA) and non-steroidal anti-inflammatory drugs (NSAID) the dose increase of Rebagit promoted faster ulcer healing during one month. Thus, the results of the study allow concluding that Rebagit can work as effective gastrocytoprotector and can repair the injured gastrointestinal mucosa under erosive and ulcerative injuries of upper gastrointestinal tract regardless of the etiologic factor.
Keywords: under erosive and ulcerative injuries of upper gastrointestinal tract, rebamipide, proton-pump inhibitors
Read entire article

Literature


  1. Осипенко М.Ф., Бикбулатова Е.А. Ребамипид – гастроинтестинальный гастропротектор с плейотропными свойствами. Эффективная фармакотерапия. 2016; 34: 28–33.

  2. Arakawa T., Kobayashi K., Yoshikawa T., Tarnawski A. Rebamipide: overview of its mechanisms of action andefficacy in mucosal protection and ulcer healing. Dig.Dis. Sci. 1998; 43(9): 5S–13S.

  3. Iijima K., Ichikawa T., Okada S. et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig. Dis. Sci. 2009; 54(7): 1500–07.

  4. Gudis K., Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig. Dis. Sci. 2005; 50(1): S16–23.

  5. Li W., Zhao Y., Xu X. et al. Rebamipide suppresses TNF-mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J. 2015; 282(12): 2317–26.

  6. Yamasaki K., Ishiyama H., Imaizumi T. et al. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jpn. J. Pharmacol. 1989; 49(4): 441–48.

  7. Lai Y., Zhong W., Yu T. et al. Rebamipide promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of β-catenin. PLoS One. 2015; 10(7): e0134122.

  8. Takeuchi K., Takayama S., Hashimoto E. et al. Effect of rebamipide on gastric bleeding and ulcerogenic responses induced by aspirin plus clopidogrel under stimulation of acid secretion in rats. J. Gastroenterol. Hepatol. 2014; 29(4): 37–46.

  9. Tomita T., Sadakata H., Tamura M., Matsui H. Indomethacin-induced generation of reactive oxygenspecies leads to epithelial cell injury before the formationof intestinal lesions in mice. J. Physiol. Pharmacol. 2014; 65(3): 435–40.

  10. Hawkey C., Burnett I., Gold M.S. et al. Endoscopic evaluation of the gastro-duodenal tolerance of shortterm analgesic treatment with 25 mg diclofenac-K liquid capsules. Aliment. Pharmacol.Ther. 2012; 35(7): 819–27.

  11. Niwa Y., Nakamura M., Ohmiya N. et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J. Gastroenterol. 2008; 43(4): 270–76.

  12. Mizukami K., Murakami K., Hirashita Y. et al. Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms. J. Clin. Biochem.Nutr. 2012; 51(3): 216–20.

  13. Arakawa T., Higuchi K., Fujiwara Y. et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig. Dis. Sci. 2005; 50(1): S3–S11.

  14. Mizukami K., Murakami K., Abe T. et al. Aspirininduced small bowel injuries and the preventive effect of rebamipide. World J. Gastroenterol. 2011; 17(46): 5117–22.

  15. Akamatsu T., Nakamura N., Furuya N. et al. Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. Dig. Dis. Sci. 2002; 47(6): 1399–1404.

  16. Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirininduced moderate-to-severe small intestinal damage. PLoS One. 2015; 10(4): e0122330.

  17. Ito Y., Sasaki M., Funaki Y. et al. Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury. J. Clin. Biochem. Nutr. 2013; 53(1): 55–59.

  18. Cho K.M., Park S.Y., Chung J.O. et al. Risk factors for small bowel bleeding in chronic nonsteroidal anti-inflammatory drug users. J. Dig. Dis. 2015; 16(90): 499–504.

  19. Han X., Jiang K., Wang B. et al. Effect of rebamipide on the premalignant progression of chronic gastritis: a randomized controlled study. Clin. Drug Investig. 2015; 35(10): 665–73.

  20. Tsukamoto H., Mizoshita T., Katano T. et al. Preventive effect of rebamipide on N-methyl-N’-nitro-Nnitrosoguanidine-induced gastric carcinogenesis in rats. Exp. Toxicol. Pathol. 2015; 67(3): 271–77.

  21. Nishizawa T., Nishizawa Y., Yahagi N. et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2014; 29(4): 20–24.

  22. Kamada T., Sato M., Tokutomi T. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res. Int. 2015. ID 865146.

  23. Kohata Y., Nakahara K., Tanigawa T. et al. Rebamipide alters the esophageal microbiome and reduces the incidence of Barrett’s esophagus in a rat model . Dig. Dis. Sci. 2015; 60(9): 2654–61.

  24. Nishizawa T., Suzuki H., Kanai T., Yahagi N. Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissectioninduced ulcer: a systematic review and meta-analysis. J. Clin. Biochem. Nutr. 2015; 56(2): 85–90.

  25. Nakamura M., Tahara T., Shiroeda H. et al. The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissectionderived artificial ulcer: a randomized controlled trial. Hepatogastroenterology. 2015; 62(137): 219–24.

  26. Xiong J., Lai S., Zhang P. et al. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014; 93(12): e64.

  27. Kurata S., Nakashima T., Osaki T. et al. Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J. Clin. Biochem.Nutr. 2015; 56(1): 20–27.

  28. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev. Gastroenterol. Hepatol. 2010; 4(3): 261–70.

  29. Moon S.J., Park J.S., Woo Y.J. et al. Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and heme oxygenase 1 induction. Arthritis Rheumatol. 2014; 66(4): 874–85.

  30. Ohguchi T., Kojima T., Ibrahim O.M. et al. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Invest. Ophthalmol. Vis. Sci. 2013; 54(12): 7793–7802.

  31. Shinohara A., Nakamura M., Onikubo T., Nakamura K. Efficacy of rebamipide gargle against chemotherapyinducedoral mucositis. YakugakuZasshi. 2015; 135: 937–41.

  32. Kudur M.H., Hulmani M. Rebamipide: a novel agent in the treatment of recurrent aphthous ulcer and Behcet’s syndrome. Indian J. Dermatol. 2013; 58(5): 352–54.

  33. Koppal S., Byatnal A.R., Rukmangada T. et al. Efficacy of rebamipide and levamisole in the treatment of patients with recurrent aphthous ulcer – a comparative study. J. Clin. Diagn.Res. 2014; 8(11): ZC119–22.

  34. Feily A., Rasaii S., Nilforoushzadeh M.A. Rebamipide as a novel addition to the antivitiligo ordnance. Int. J. Clin. Pharmacol. Ther. 2015; 53(12): 1035–36.

  35. Kim J.H., Park S.H., Cho C.S. et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014; 8(4): 371–79.

  36. Park S.H., Cho C.S., Lee O.Y. et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J. Clin. Biochem. Nutr. 2007; 40(2): 148–55.

  37. Murrell D.E., Rahmasari Y., Denham J.W. et al. Celecoxib or diclofenac hepatic status in the presence or absence of rebamipide. Eur. Rev. Med. Pharmacol. Sci. 2015; 19(17): 3318–25.

  38. Lanas A., Carrera-Lasfuentes P., Arguedas Y., García S., Bujanda L., Calvet X., Ponce J., Perez-Aisa A., Castro M., Munoz M., Sostres C., Garcia-Rodriguez L.A. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015; 13: 906–912.e2.

  39. Juurlink D.N., Gomes T., Ko D.T. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180(7): 713–18.


About the Autors

Venera E. Sagynbaeva, PhD, gastroenterologist of City clinical hospital No 1 named after N.I. Pirogov of the Department of Healthcare of Moscow. Address: 119049, Moscow, 8 Leninskij prospekt. Tel.: +7 (499) 764-50-02.
Leonid B. Lazebnik, MD, professor of the Department of outpatient therapy of A.I. Yevdokimov Moscow State University of medicine and dentistry, president of the Scientific Society of Gastroenterologists of Russia, Vice-President of the Russian Scientific Medical Society of Therapists. Address: 127473, Moscow, 20/1 Delegatskaya Str.
Tel.: +7 (985) 920-83-42. E-mail: leonid.borisl@gmail.com

Back to Content

Бионика Медиа